Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

By sjmartinez • February 1, 2023

Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406. Epub ahead of print. PMID: 36720582.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Supporting Educational Excellence in Diversity (SEED): faculty development and allyship

Chadha P, Kang EH, Ngo V, Jorrin R, Kochai K, Ackerman-Barger K, Ton H. Supporting Educational Excellence in Diversity (SEED): faculty development and allyship. BMC[...]

Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States

Pak K, Sachar R, Saab S. Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase[...]

General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site, retrospective study

Soumekh L, Bell S, Espinosa SL, Grogan T, Kesavan K, Calkins KL. General movement assessments in neonates born with congenital gastrointestinal anomalies: a single site,[...]